Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the regimen of Merck's Emend for Injection/Ivemend combined with 5-HT3 RA, is positioned to earn gold-standard status in the treatment of chemotherapy-induced nausea and vomiting by 2011. The regimen of Emend for Injection/Ivemend and 5-HT3 RA offers robust efficacy and key advantages in delivery as a result of its availability in a single-dose IV formulation that is more convenient than the three-consecutive-day-dosing schedule of Merck's Emend, the current gold standard.
The new report entitled Chemotherapy-Induced Nausea and Vomiting: Physician Satisfaction with Inexpensive Antiemetics Sets High Hurdles for Reformulations and Emerging Agents, also finds that GlaxoSmithKline's Rezonic, launching in 2009 as the second-to-market NK1 RA, is positioned as the only emerging agent, compared with Emend, with the potential to demonstrate better control over delayed chemotherapy-induced nausea and vomiting in patients taking highly emetogenic chemotherapy. Preliminary data from clinical trials show that the addition of oral Rezonic to GlaxoSmithKline's Zofran and Merck/Banyu's Decadron result in an 86 percent of patients with no emetic episodes and do not require rescue therapy compared with Emend's 68 percent; however, more data is needed to confirm the effect on delayed chemotherapy-induced nausea and vomiting. Additionally, unless Rezonic shows extraordinary efficacy or is priced much lower than currently available NK1 antagonists, it is not expected to gain more patient share than the Emend franchise owing to Emend's first-to-market status in the injectable NK1 antagonist class.
"Even if Rezonic meets the challenge in reducing chemotherapy-induced nausea and vomiting, it will face stiff competition from Emend and Emend for Injection/Ivemend as a result of these agents' earlier launches and lower prices," said Nancy Li, analyst at Decision Resources. "In an increasingly budget-conscious healthcare environment, payers may not be willing to reimburse a premium for small improvements in efficacy, safety, tolerability and delivery."
About the Report
Chemotherapy-Induced Nausea and Vomiting: Physician Satisfaction with Inexpensive Antiemetics Sets High Hurdles for Reformulations and Emerging Agents is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (www.decisionresources.com), is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 firstname.lastname@example.org
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
Web site: http://www.decisionresources.com/